GLP-1s and a Rare Brain Injury: 13 of 15 Cases Had a Warning Sign First
Author
Date Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
A study in Clinical Nutrition found 15 reported cases of Wernicke encephalopathy, a brain injury caused by severe vitamin B1 deficiency, in people taking GLP-1 medications. While this isn’t a new condition specific to GLP-1 users, it has been trending again in the news for a good reason - it’s a valid and concerning health issue that can happen in a few specific situations. In 13 of the 15 cases reported, vomiting, poor appetite, weight loss or malnutrition came first, which is the stage where it can be caught and treated. Nothing here means you should stop a prescribed medication. It means knowing what to watch for.
Who This Helps
This is for you if the headlines worried you, or if you've been pushing through weeks of nausea on Ozempic, Wegovy, Mounjaro or Zepbound because you assumed it was part of it. For more typical side effects, our piece on what week six actually looks like is the better read. This one covers the rare thing.
Nearly every case had a nutritional problem first
13 of the 15 patients had gastrointestinal or nutritional trouble before any neurological symptoms: vomiting, loss of appetite, weight loss, or malnutrition (Clinical Nutrition). It’s important to note the presence of warning signs because it shows this doesn’t come out of nowhere, and should be caught under normal monitoring by a prescriber.
In cases where the patients had bariatric surgery, the literature shows the same pattern. In a review of 118 surgical cases, 87.3% had vomiting (Obesity Surgery). Same destination by a different route: weeks of not keeping food down.
Nausea and vomiting are common on weight-loss medications and usually nothing like this. In the STEP 1 trial, 44.2% of participants reported nausea and 24.8% reported vomiting, described as typically transient, mild to moderate, and subsiding with time (New England Journal of Medicine). The question that matters is how long it has gone on.
- Call your prescriber if: vomiting or diarrhea keeps going for days rather than hours, you can't keep fluids down, or you've stopped eating much of anything. If that has already been going on a week or more, call now rather than waiting to see whether it passes.
- Go to an emergency room for: new confusion, memory trouble, double or blurred vision, or unsteadiness on your feet, particularly after a stretch of poor intake. These are treated as emergencies.
- Higher risk if: you've had bariatric surgery, you drink heavily, you're losing weight very fast while eating very little, or you're vomiting regularly.
What the study found, and what it can't tell you
Researchers pulled 15 cases: 13 from the FDA's adverse event database, one from published literature, one from their own medical center. Eight involved semaglutide and six involved tirzepatide. Fourteen were reported in 2023 and 2024 (Clinical Nutrition).
The statistic driving the coverage is a reporting odds ratio of 2.35, with a 95% confidence interval of 1.38 to 4.01. Roughly, the condition was reported about 2.35 times more often alongside GLP-1 medications than alongside other drugs. While the sample size studied is small, it’s an indication of concern not a guarantee.
What that number is not is a rate. The FDA says so about this database: "information in these reports cannot be used to estimate the incidence (occurrence rates) of the reactions reported," and "existence of a report does not establish causation" (FDA). Reporting also climbs when a drug is in the news, a documented effect in this database known as notoriety bias (Hospital Pharmacy). The authors called it "a potentially rare but severe adverse event" and asked for greater clinical awareness, particularly in people with severe gastrointestinal symptoms (study authors).
One limit deserves saying plainly. The vomiting and appetite loss that precede these cases are themselves known effects of the medication, so pointing at poor history intake as the reason this is happening doesn't let the drug off the hook. It identifies where the chain can be broken, but also where prescribers can better support those who qualify to use GLP-1s in their treatment.
The condition is serious, and it's genuinely easy to miss
Wernicke encephalopathy comes from running out of thiamine, which is vitamin B1. Your body doesn't store much, and clinical references put depletion at roughly two weeks of limited intake (StatPearls). It's best known in alcohol use disorder, but prolonged vomiting, severe malnutrition and bariatric surgery do it too.
The textbook description is three things together: confusion, eye movement problems, and an unsteady walk. Waiting for that combination is how it gets missed. Only about 16% of patients show all three, and roughly 19% have none of the classic symptoms when first seen (Frontiers in Neurology). In this study, 2 of the 15 had the full triad.
Among the 11 patients with follow-up data, 7 had lasting neurological problems. Treatment is thiamine by IV, started on suspicion rather than after a blood test or scan, since "negative imaging should not delay the initiation of treatment." Starting early gives the best chance, and even then complete resolution is often not achieved, with memory and walking recovering least well (StatPearls). Because early treatment is recommended even without all the symptoms, and leaving it to go on longer can lead to lasting impacts, you should be aware of this issue and discuss the likelihood with your prescriber if you’re concerned.
What responsible use looks like
Both labels build in a slow ramp for this reason, telling prescribers to follow the escalation schedule "to reduce the risk of gastrointestinal adverse reactions" (Wegovy prescribing information) (Zepbound prescribing information). Both also say what to do when a dose doesn't sit well: Wegovy's is to "consider delaying dosage escalation for 4 weeks," Zepbound's to "consider a lower maintenance dosage." Staying at a tolerable dose is in the label, and staying at a low dose isn't failing at anything.
On food, four professional societies published a joint advisory on GLP-1 nutrition in 2025. It suggests 1.2 to 1.6 g of protein per kilogram daily during active weight loss, or 80 to 120 g a day, and flags that intakes below 1,200 calories for women and 1,800 for men make it hard to get enough vitamins and minerals (joint advisory from four professional societies). On supplements it's measured, saying they "can be proactively considered for at-risk nutrients" and tailored to the person. B1 is on its list of nutrients of concern.
Two things to keep in mind with any news trending. No trial has tested whether slower weight loss lowers this particular risk, so the case for a gradual ramp rests on mechanism and the label's own reasoning. And the pivotal trials never measured thiamine, so they can't be cited as evidence it doesn't happen. Those trials did give participants counseling every four weeks, more nutritional support than many people get (New England Journal of Medicine). Our piece on what walking actually buys you covers the movement side.
Bariatric surgery has a thiamine protocol. GLP-1 nutrition guidance is newer.
Neither label mentions thiamine, vitamin deficiency or malnutrition anywhere. The American Society for Metabolic and Bariatric Surgery, meanwhile, has a dedicated 2025 guideline on preventing, diagnosing and treating this exact condition in surgical patients (ASMBS). The joint nutrition advisory is a real step, and it stops short of a comparable thiamine protocol. Basically, this is a known issue in weight loss treatments, and because GLP-1s are newer to the game, they haven’t yet caught up on the protocol to avoid.
So tell your prescriber about persistent vomiting rather than wait to be asked, and tell any clinician treating you that you're on a GLP-1, the same way it matters before a scheduled procedure.
Final Takeaway
Fifteen reported cases is a small number, and the FDA's database can't tell us the true rate, only that the pattern deserves attention. What makes it usable is that it came with a warning attached. Almost everyone affected had weeks of vomiting, poor appetite or dropping weight before anything neurological started. Eat enough, drink enough, don't white-knuckle your way through weeks of being unable to keep food down, and tell your prescriber when something isn't settling. Don't stop a prescribed medication over a headline. Don't ignore your body to stay on one.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Frequently Asked Questions
Should I stop taking my GLP-1 because of this study?
No, and the researchers didn't suggest that. They asked for more clinical awareness, particularly in people with severe gastrointestinal symptoms. If you're worried, the conversation to have with your prescriber is about your appetite, your intake and any vomiting.
What are the early symptoms of vitamin B1 deficiency?
The ones to act on are confusion, memory problems, vision changes including double vision, and unsteadiness when walking, especially after poor eating or ongoing vomiting. The complete set of classic symptoms appears in only about 16% of cases, so one new symptom after weeks of low intake is reason enough to be seen.
Should I take a vitamin B1 supplement while on a GLP-1?
That's a question for your prescriber rather than a blanket yes. The 2025 joint advisory stops short of recommending routine supplementation for everyone, saying supplements can be considered for at-risk nutrients and tailored to the individual. People with bariatric surgery history, heavy alcohol use or prolonged vomiting are likeliest to need a plan.
Sources
Find a provider in your state
Answer a few questions and see live pricing from the providers that ship where you live.
Keep Reading
An Australian lab tested 18 vials sold as retatrutide. One matched its label. See what the dosing errors were and why a purity test proves little.
PCOS was renamed PMOS in 2026. See what the pooled randomized evidence on GLP-1s actually found, and why a PMOS diagnosis will not unlock coverage.
Turnkey platforms let almost anyone launch a GLP-1 clinic, one vendor says daily. See why prices fell, where the risk sits, and the 3 names to ask for
Categories
Written by
Lauren PescarusLauren Pescarus is a team member with GLP Winner where she works on marketing, content creation, and operations. She has over 10 years experience in the content creation space, including in the GLP-1 space where she works to stay on top of access news, research updates, and lifestyle tips guided by science.